ATED Therapeutics develops diagnostics and therapeutics for Parkinson’s disease and other central nervous system diseases. Its lead product is an investigational transfer RNA fragment blood test intended to help detect Parkinson’s earlier, monitor disease progression, and quantify response to deep brain stimulation. The company also reports development of two disease-modifying Parkinson’s drug candidates.